Bryan Johnson· Author
Psilocybin reduced my inflammation (hsCRP) to below detectable levels one week post dose.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Psilocybin reduced my inflammation (hsCRP) to below detectable levels one week post dose.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Inflammation A single psilocybin dose reduced TNF-α, CRP, and IL-6. Systemic inflammation markers tied to aging.
A clinical trial involving 60 healthy participants (30 psilocybin, 30 placebo) demonstrated that a single, relatively high dose (0.17mg/kg) of psilocybin led to immediate reductions in TNF-alpha, with further reductions in CRP and IL-6 observed seven days post-dosing.
Psilocybin reduced my inflammation (hsCRP) to below detectable levels one week post dose.
My systematic inflammation levels dropped from elite to undetectable. This decrease is significant, aligning with clinical reports of reduced inflammation markers (CRP, TNF-alpha, and IL6) seven days post high dose psilocybin.